Patents by Inventor Lykke Pedersen

Lykke Pedersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
    Patent number: 11484546
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: November 1, 2022
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Susanne Kammler, Anaïs Lopez, Henrik Mueller, Søren Ottosen, Lykke Pedersen
  • Oligonucleotides for reduction of PD-L1 expression
    Patent number: 11466081
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: October 11, 2022
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
  • ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTEL1 EXPRESSION
    Publication number: 20220251556
    Abstract: Enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity are provided. This disclosure relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. This disclosure further relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. A pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection is also described.
    Type: Application
    Filed: February 1, 2022
    Publication date: August 11, 2022
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Erik FUNDER, Natascha HRUSCHKA, Susanne KAMMLER, Erich KOLLER, Brian LEONARD, Souphalone LUANGSAY, Susanne MOHR, Tobias NILSSON, Søren OTTOSEN, Lykke PEDERSEN, Søren V. RASMUSSEN, Steffen SCHMIDT, Sabine SEWING, Daniel TURLEY, Johanna Marie WALTHER
  • Antisense Oligonucleotides Targeting ATXN3
    Publication number: 20220177883
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to ATXN3 pre-mRNA sequences, which are capable of inhibiting the expression of ATXN3 protein. Inhibition of ATXN3 expression is beneficial for the treatment of spinocerebellar ataxia.
    Type: Application
    Filed: December 2, 2021
    Publication date: June 9, 2022
    Inventors: Heidi Rye Hudlebusch, Lykke Pedersen, Erik Funder, Lukasz Kielpinski, Christoffer Sondergaard, Alexander Herbert Stephan
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20220146496
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 12, 2022
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Oligonucleotides for inducing paternal UBE3A expression
    Patent number: 11320421
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: May 3, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Oligonucleotides for modulating ATXN2 expression
    Patent number: 11286485
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of ATXN2 in a target cell. The oligonucleotides hybridize to ATXN2 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), Alzheimer's frontotemporal dementia (FTD), parkinsonism and conditions with TDP-43 proteinopathies using the oligonucleotide.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: March 29, 2022
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Peter Hagedorn, Dennis Jul Hansen, Heidi Rye Hudlebusch, Lykke Pedersen, Søren Vestergaard Rasmussen, Mette Ladefoged
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
    Publication number: 20220042022
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: August 17, 2021
    Publication date: February 10, 2022
    Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
  • ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION
    Publication number: 20220031730
    Abstract: The present invention relates to enhanced antisense oligonucleotides that are complementary to the Far Upstream Element-Binding Protein 1 (FUBP1) and are capable of reducing a FUBP1 target nucleic acid, such as FUBP1 mRNA. The invention relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention in particular relates to the use of the enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for destabilizing cccDNA, such as HBV cccDNA. The invention further relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating cancer. A pharmaceutical composition and its use in the treatment and/or prevention of an HBV infection, or its use in the treatment of cancer is also disclosed.
    Type: Application
    Filed: June 25, 2021
    Publication date: February 3, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sabine SEWING, Søren OTTOSEN, Jacob RAVN, Lykke PEDERSEN, Souphalone LUANGSAY, Erich KOLLER, Johanna Marie WALTHER, Helene Maria GYLLING, Natascha HRUSCHKA, Susanne MOHR, Valentina D'ARIENZO
  • ANTISENSE OLIGONUCLEOTIDES TARGETING TIA1
    Publication number: 20210261961
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) complementary to nucleic acids encoding mammalian T cell-restricted intracellular antigen-1 (TIA1), in particular antisense oligonucleotides targeting TIA1 pre-mRNA sequences, which are capable of inhibiting the expression of TIA1. Inhibition of TIA1expression is beneficial for a range of medical disorders including neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) or Frontotemporal Dementia.
    Type: Application
    Filed: April 30, 2021
    Publication date: August 26, 2021
    Inventors: Veronica COSTA, Heidi Rye HUDLEBUSCH, Ravi JAGASIA, Dheeraj MALHOTRA, Lykke PEDERSEN
  • OLIGONUCLEOTIDES FOR MODULATING SCN9A EXPRESSION
    Publication number: 20210238608
    Abstract: The present invention relates to oligonucleotides (oligomers) that are complementary to voltage-gated sodium ion channel encoding nucleic acids, such as SCN9A, which encodes the voltage-gated sodium channel Nav1.7. The oligonucleotides of the invention are capable of inhibiting the expression of voltage-gated sodium ion channels, such as Nav1.7, and are useful in the prevention or the treatment of pain.
    Type: Application
    Filed: December 22, 2020
    Publication date: August 5, 2021
    Inventors: Lykke PEDERSEN, Søren RASMUSSEN, Gianluigi LICHINCHI, Christoffer SONDERGAARD
  • Oligonucleotides for modulating ATXN2 expression
    Patent number: 11066669
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of ATXN2 in a target cell. The oligonucleotides hybridize to ATXN2 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), Alzheimer's frontotemporal dementia (FTD), parkinsonism and conditions with TDP-43 proteinopathies using the oligonucleotide.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: July 20, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Hagedorn, Heidi Rye Hudlebusch, Lykke Pedersen, Søren V. Rasmussen
  • ENHANCED OLIGONUCLEOTIDES FOR INHIBITING SCN9A EXPRESSION
    Publication number: 20210214727
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of SCN9A in a target cell. The antisense oligonucleotides hybridize to SCN9A mRNA. The present invention further relates to conjugates of the antisense oligonucleotide and pharmaceutical compositions and methods for treatment of or prevention of pain, such as peripheral pain.
    Type: Application
    Filed: December 18, 2020
    Publication date: July 15, 2021
    Inventors: Lykke PEDERSEN, Søren V. RASMUSSEN
  • OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION
    Publication number: 20210147850
    Abstract: The present invention relates to a RTEL1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of RTEL1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to antisense oligonucleotides which are complementary to RTEL1 and capable of reducing a RTEL1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 20, 2021
    Inventors: Marco BERRERA, Josephine FELBER, Jean-Christophe HOFLACK, Susanne KAMMLER, Tony KAM-THONG, Brian LEONARD, Lykke PEDERSEN, Philipp TROPBERGER, Miriam TRIYATNI, Daniel Jeremy TURLEY, Angelina WALLIER, Jitao David ZHANG
  • OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION
    Publication number: 20210147535
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Application
    Filed: August 21, 2020
    Publication date: May 20, 2021
    Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Søren OTTOSEN, Souphalone LUANGSAY
  • OLIGONUCLEOTIDES FOR MODULATING GSK3B EXPRESSION
    Publication number: 20210095275
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of GSK3B in a target cell. The antisense oligonucleotides hybridize to GSK3B pre-mRNA. The present invention further relates to conjugates of the antisense oligonucleotide, pharmaceutical salts and pharmaceutical compositions and methods for treatment or alleviation of conditions such as cancer, inflammatory diseases, neurological diseases, neurological injury, neuronal degeneration, psychiatric diseases and Type 2 diabetes.
    Type: Application
    Filed: January 10, 2019
    Publication date: April 1, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Peter HAGEDORN, Lykke PEDERSEN
  • OLIGONUCLEOTIDES FOR MODULATING ERC1 EXPRESSION
    Publication number: 20210095276
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of ERC1 in a target cell. The oligonucleotides hybridize to ERC1 pre-mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of disease associated with ERC1 overexpression, such as cancer or Dengue virus infection using the antisense oligonucleotide.
    Type: Application
    Filed: January 15, 2019
    Publication date: April 1, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Peter HAGEDORN, Lykke PEDERSEN
  • OLIGONUCLEOTIDES FOR MODULATING PIAS4 EXPRESSION
    Publication number: 20210095274
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of PIAS4 in a target cell. The antisense oligonucleotides hybridize to PIAS4 pre-mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of cancers such as pancreatic cancer, breast cancer and liver fibrosis using the antisense oligonucleotide.
    Type: Application
    Filed: January 8, 2019
    Publication date: April 1, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Peter HAGEDORN, Lykke PEDERSEN
  • Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
    Patent number: 10953034
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 23, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Susanne Kammler, Anaïs Lopez, Henrik Mueller, Søren Ottosen, Lykke Pedersen
  • OLIGONUCLEOTIDES FOR MODULATING ATXN2 EXPRESSION
    Publication number: 20210024925
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of ATXN2 in a target cell. The oligonucleotides hybridize to ATXN2 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), Alzheimer's frontotemporal dementia (FTD), parkinsonism and conditions with TDP-43 proteinopathies using the oligonucleotide.
    Type: Application
    Filed: April 3, 2020
    Publication date: January 28, 2021
    Inventors: Peter Hagedorn, Dennis Jul Hansen, Heidi Rye Hudlebusch, Lykke Pedersen, Søren Vestergaard Rasmussen, Mette Ladefoged